Nuvalent, Inc.

Nuvalent, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing precisely targeted small-molecule therapies for cancer. Its pipeline centers on kinase inhibitors, including zidesamtinib for ROS1-positive non-small cell lung cancer, neladalkib for ALK-driven cancers, and NVL-330 for HER2-driven cancers, with development and planned commercialization primarily in the United States.

15.27

15.27

— Nuvalent, Inc.
%
ROS1-targeted therapy0% Small-molecule therapy designed for ROS1-positive cancers, centered on zidesamtinib.
ALK-targeted therapy0% Small-molecule therapy designed for ALK-driven cancers, centered on neladalkib.
HER2-targeted therapy0% Small-molecule therapy designed for HER2-driven cancers, centered on NVL-330.
Discovery programs0% Earlier-stage oncology research programs aimed at additional kinase targets.
Commercialization preparation0% Sales, market access, marketing, and supply-chain readiness for future launches.

Nuvalent’s direct customers are not yet commercial buyers; its future customers are oncologists, hospitals, and cancer...

  • Oncology prescribersprimary

    Specialist physicians who would prescribe zidesamtinib, neladalkib, or NVL-330 based on biomarker status and clinical profile.

  • Cancer treatment centersprimary

    Hospitals and infusion/oncology centers that administer targeted cancer therapies and manage patient pathways.

  • Third-party payorsprimary

    Commercial insurers and government payors that determine reimbursement and access for approved oncology drugs.

  • Clinical trial sitessecondary

    Academic and community sites that enroll patients into Nuvalent’s development studies and generate clinical evidence.

Nuvalent is headquartered in Cambridge, Massachusetts and is building its initial commercial footprint in the United...

  • •Headquartered in Cambridge, Massachusetts
  • •Primary commercial focus is the United States
  • •Worldwide development and commercialization rights retained
  • •Potential ex-U.S. launch may use partners or direct sales
  • •Manufacturing and logistics are outsourced to third parties

Nuvalent’s strategy is to advance highly selective kinase inhibitors through clinical development and prepare for a...

01
Advance lead oncology assets through clinical developmentshort-term

Clinical success is the main value driver for a pre-revenue biotech and determines approval odds.

02
Build commercial launch readiness in the U.S.short-term

A targeted launch requires sales, market access, and marketing infrastructure before approval.

03
Preserve flexibility for ex-U.S. commercializationmedium-term

International rights can be monetized directly or through partners depending on market size and execution needs.

04
Expand the discovery pipelinemedium-term

Additional programs can diversify scientific risk and extend the company’s oncology platform.

Nuvalent faces the typical risks of a clinical-stage biotech: clinical failure, regulatory delay, and uncertainty...

critical

Clinical development failure

The company’s value depends on proving safety and efficacy in later-stage trials.

Scope
zidesamtinib, neladalkib, NVL-330
Materiality
high
high

Regulatory approval risk

Marketing approval is required before any product revenue can begin.

Scope
FDA and other regulators
Materiality
high
high

Competitive pressure

Approved kinase inhibitors and antibody-drug conjugates already serve these targets.

Scope
ROS1, ALK, HER2 oncology markets
Materiality
high
high

Reimbursement and market access

Coverage decisions by payors can limit adoption even after approval.

Scope
U.S. commercial launch
Materiality
high
medium

Third-party manufacturing dependence

The company does not own manufacturing facilities and relies on CMOs for supply.

Scope
clinical and commercial supply chain
Materiality
medium
Related party revenue share liability
Changes in assumptions can materially affect other income/expense and liabilities
Clinical trial and manufacturing accruals
Can cause quarter-to-quarter swings in R&D expense
Stock-based compensation
Affects operating expense and reported losses

Nuvation Bio Inc.

NUVB · Pharmaceutical Preparations

Nuvectis Pharma, Inc.

NVCT · Pharmaceutical Preparations

Cogent Biosciences, Inc.

COGT · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN · Pharmaceutical Preparations

Zentalis Pharmaceuticals, Inc.

ZNTL · Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

: 29/04/2026